共 455 条
[31]
Walsh T(2008)Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent Clin Cancer Res 14 5869-1208
[32]
Ward R(2009) hybridization study Clin Cancer Res 15 3184-1197
[33]
Hawkins N(2010)PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer J Clin Oncol 38 466-6069
[34]
Beranek M(2004)Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 22 1201-1857
[35]
Jandik P(2000)Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor Cancer Epidemiol Biomarkers Prev 9 1193-472
[36]
Benamouzig R(2005)Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study Cancer Res 65 6063-209
[37]
Jullian E(2009)Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res 69 1851-64
[38]
Laurent-Puig P(2009)PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Br J Cancer 101 465-undefined
[39]
Olschwang S(2005)Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer N Engl J Medicine 353 208-undefined
[40]
Muller O(2002)Responsiveness to cetuximab without mutations in EGFR Science 297 63-undefined